$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

Cancer discovery, v.2 no.3, 2012년, pp.270 - 287  

Sennino, Barbara ,  Ishiguro-Oonuma, Toshina ,  Wei, Ying ,  Naylor, Ryan M. ,  Williamson, Casey W. ,  Bhagwandin, Vikash ,  Tabruyn, Sebastien P. ,  You, Weon-Kyoo ,  Chapman, Harold A. ,  Christensen, James G. ,  Aftab, Dana T. ,  McDonald, Donald M.

Abstract AI-Helper 아이콘AI-Helper

AbstractInvasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the present study we asked whether selective VEGF inhibition is sufficient to increase invasion and metastasis and whether selective c-Met inhibition is sufficient to block this effec...

참고문헌 (64)

  1. Nature Ferrara 438 967 2005 10.1038/nature04483 Angiogenesis as a therapeutic target 

  2. Nat Rev Cancer Ellis 8 579 2008 10.1038/nrc2403 VEGF-targeted therapy: mechanisms of anti-tumour activity 

  3. Neoplasia Rubenstein 2 306 2000 10.1038/sj.neo.7900102 Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption 

  4. Cancer Cell Casanovas 8 299 2005 10.1016/j.ccr.2005.09.005 Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors 

  5. Cancer Cell Ebos 15 232 2009 10.1016/j.ccr.2009.01.021 et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis 

  6. Cancer Cell Paez-Ribes 15 220 2009 10.1016/j.ccr.2009.01.027 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis 

  7. Nature Bottaro 423 593 2003 10.1038/423593a Cancer: out of air is not out of action 

  8. Cancer Cell Pennacchietti 3 347 2003 10.1016/S1535-6108(03)00085-0 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene 

  9. J Cell Physiol Benvenuti 213 316 2007 10.1002/jcp.21183 The MET receptor tyrosine kinase in invasion and metastasis 

  10. Nat Rev Mol Cell Biol Trusolino 11 834 2010 10.1038/nrm3012 MET signalling: principles and functions in development, organ regeneration and cancer 

  11. Proc Natl Acad Sci U S A Graveel 106 12909 2009 10.1073/pnas.0810403106 Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer 

  12. Proc Natl Acad Sci U S A Ponzo 106 12903 2009 10.1073/pnas.0810402106 Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer 

  13. Cancer Ghoussoub 82 1513 1998 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7 Expression of c-met is a strong independent prognostic factor in breast carcinoma 

  14. Cancer Kong 115 140 2009 10.1002/cncr.23972 Prognostic significance of c-Met expression in glioblastomas 

  15. Cancer Res Sawada 67 1670 2007 10.1158/0008-5472.CAN-06-1147 c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion 

  16. Int J Cancer Lengyel 113 678 2005 10.1002/ijc.20598 C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu 

  17. Trends Cell Biol Lai 19 542 2009 10.1016/j.tcb.2009.07.002 Crosstalk in Met receptor oncogenesis 

  18. Oncogene Xu 29 2616 2010 10.1038/onc.2010.16 Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells 

  19. Cancer Res You 71 4758 2011 10.1158/0008-5472.CAN-10-2527 VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer 

  20. Proc Natl Acad Sci U S A Cullen 108 5759 2011 10.1073/pnas.1017192108 GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier 

  21. Biochemistry Timofeevski 48 5339 2009 10.1021/bi900438w Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors 

  22. Mol Cancer Res Fleming 3 413 2005 10.1158/1541-7786.MCR-04-0206 Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy 

  23. Int J Cancer Qian 104 542 2003 10.1002/ijc.10997 Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells 

  24. Nature Hanahan 315 115 1985 10.1038/315115a0 Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes 

  25. Science Bergers 284 808 1999 10.1126/science.284.5415.808 Effects of angiogenesis inhibitors on multistage carcinogenesis in mice 

  26. Int J Cancer Beck 118 2639 2006 10.1002/ijc.21684 Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice 

  27. Ann Oncol Christensen 18 Suppl 10 x3 2007 10.1093/annonc/mdm408 A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities 

  28. J Bone Miner Res Sampson 26 1283 2011 10.1002/jbmr.336 The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model 

  29. Oncogene Dulak 30 3625 2011 10.1038/onc.2011.84 HGF-independent potentiation of EGFR action by c-Met 

  30. J Clin Oncol Kurzrock 29 2660 2011 10.1200/JCO.2010.32.4145 Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer 

  31. J Clin Oncol Hussain 29 2011 10.1200/jco.2011.29.15_suppl.4516 Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial 

  32. Mol Cancer Ther Yakes 10 2298 2011 10.1158/1535-7163.MCT-11-0264 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth 

  33. Gastroenterology Li 141 2218 2011 10.1053/j.gastro.2011.08.009 c-Met is a marker of pancreatic cancer stem cells and therapeutic target 

  34. Am J Pathol Inai 165 35 2004 10.1016/S0002-9440(10)63273-7 Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts 

  35. Mol Cancer Ther Christensen 6 3314 2007 10.1158/1535-7163.MCT-07-0365 Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma 

  36. J Surg Res Bloomston 102 39 2002 10.1006/jsre.2001.6318 TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis 

  37. Mol Pharmacol Gaspar 72 152 2007 10.1124/mol.106.029025 Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness 

  38. Cancer Bruns 89 488 2000 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.0.CO;2-X Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases 

  39. Nature Pouyssegur 441 437 2006 10.1038/nature04871 Hypoxia signalling in cancer and approaches to enforce tumour regression 

  40. J Cell Biol Wang 153 1023 2001 10.1083/jcb.153.5.1023 Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice 

  41. Cancer Res Yu 62 2951 2002 Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model 

  42. J Biol Chem Jo 275 8806 2000 10.1074/jbc.275.12.8806 Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells 

  43. Proc Natl Acad Sci U S A Wang 93 8425 1996 10.1073/pnas.93.16.8425 Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor 

  44. Cancer Res McDermott 70 1625 2010 10.1158/0008-5472.CAN-09-3620 Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency 

  45. Cancer Res Qi 71 1081 2011 10.1158/0008-5472.CAN-10-1623 Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors 

  46. Cancer Cell Lopez 1 339 2002 10.1016/S1535-6108(02)00055-7 Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis 

  47. Nat Rev Cancer Bergers 8 592 2008 10.1038/nrc2442 Modes of resistance to anti-angiogenic therapy 

  48. Proc Natl Acad Sci U S A Chun 107 17268 2010 10.1073/pnas.1012705107 Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis 

  49. Clin Sci (Lond) Santibanez 121 233 2011 10.1042/CS20110086 TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions 

  50. Oncogene Moghul 9 2045 1994 Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript 

  51. Mol Cancer Res Cheng 6 1521 2008 10.1158/1541-7786.MCR-07-2203 Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion 

  52. Nature Perl 392 190 1998 10.1038/32433 A causal role for E-cadherin in the transition from adenoma to carcinoma 

  53. Nat Rev Cancer Thiery 2 442 2002 10.1038/nrc822 Epithelial-mesenchymal transitions in tumour progression 

  54. Cancer Metastasis Rev Yilmaz 28 15 2009 10.1007/s10555-008-9169-0 EMT, the cytoskeleton, and cancer cell invasion 

  55. Nat Rev Mol Cell Biol Nieto 3 155 2002 10.1038/nrm757 The snail superfamily of zinc-finger transcription factors 

  56. J Neurosurg Narayana 110 173 2009 10.3171/2008.4.17492 Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival 

  57. Cancer Cell Michieli 6 61 2004 10.1016/j.ccr.2004.05.032 Targeting the tumor and its microenvironment by a dual-­function decoy Met receptor 

  58. Clin Cancer Res Peruzzi 12 3657 2006 10.1158/1078-0432.CCR-06-0818 Targeting the c-Met signaling pathway in cancer 

  59. Cancer Res Jin 68 4360 2008 10.1158/0008-5472.CAN-07-5960 MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival 

  60. Proc Natl Acad Sci U S A Gjerdrum 107 1124 2010 10.1073/pnas.0909333107 Axl is an essential epithelial-to-mesenchymal transition-­induced regulator of breast cancer metastasis and patient survival 

  61. Cancer Res Qian 69 8009 2009 10.1158/0008-5472.CAN-08-4889 Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases 

  62. Cancer Sci Nakagawa 101 210 2010 10.1111/j.1349-7006.2009.01343.x E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models 

  63. Biol Cell Sulpice 101 525 2009 10.1042/BC20080221 Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells 

  64. Am J Pathol Dai 167 429 2005 10.1016/S0002-9440(10)62987-2 Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance 

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트